The future therapy of autoimmune diseases will be characterized by drugs that will allow specific therapy with only minimum side effects (so-called “biologicals”).
The worldwide sales of some “biologicals" already exceeds one billion EURO. Diseases like psoriasis affecting 2-3% of the population even have the potential to develop to a multi-billion EURO market.
Also less common autoimmune diseases like systemic lupus erythematosus (SLE) offer promising market potentials.
Initial success in the AESKU.THERAPY business line demonstrates that new so-called “biologicals" may allow specific therapy with only minimum side effects. Due to high complexity of the matter and considerable financial requirements, AESKU.DIAGNOSTICS intends to find cooperation partners for its AESKU.THERAPY business line to support marketing and registration of such therapeutics.
|
